Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Johnson & Johnson has submitted its esketamine for regulatory approval, but researchers still don't understand how the fast-acting antidepressant lifts moods.
Martin VanTrieste, CEO of Civica Rx and former chief quality officer for Amgen, discusses how his hospital-backed non-profit generic drug company plans to bring stability to the generic drug market.